Search

Your search keyword '"Boesjes, Celeste M."' showing total 40 results
Start Over Author "Boesjes, Celeste M."
40 results on '"Boesjes, Celeste M."'

1. Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry

Author

Zhang, Junfen, Boesjes, Celeste M., Loman, Laura, Kamphuis, Esmé, Romeijn, Margreet L.E., Spekhorst, Lotte S., Haeck, Inge, van der Gang, Lian F., Dekkers, Coco C., van der Rijst, Lisa P., Oosting, Albert J., van Lumig, Paula, van Lynden-van Nes, Anneke M.T., Tupker, Ron A., Nijssen, Annieke, Flinterman, Annebeth, Politiek, Klaziena, Touwslager, Wouter R.H., Christoffers, Wianda A., Stewart, Shiarra M., Kamsteeg, Marijke, de Graaf, Marlies, de Bruin-Weller, Marjolein S., and Schuttelaar, Marie-Louise A.

Published
2024
Full Text
View/download PDF

2. Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic Dermatitis.

Author

Boesjes, Celeste M., Kamphuis, Esmé, de Graaf, Marlies, Spekhorst, Lotte S., Haeck, Inge, van der Gang, Lian F., Loman, Laura, Zuithoff, Nicolaas P. A., Dekkers, Coco, van der Rijst, Lisa P., Romeijn, Geertruida L. E., Oosting, Albert J., Gostynksi, Antoni, van Lynden-van Nes, Anneke M. T., Tupker, Ron A., van Tuyll van Serooskerken, Anne-Moon, Flinterman, Annebeth, Politiek, Klaziena, Touwslager, Wouter R. H., and Christoffers, Wianda A.

Published
2024
Full Text
View/download PDF

3. Single Cell Sequencing of Human Langerhans Cells Identifies Altered Gene Expression Profiles in Patients with Atopic Dermatitis

Author

Tamminga, Sara M., primary, van der Wal, M. Marlot, additional, Saager, Elise S, additional, van der Gang, Lian F, additional, Boesjes, Celeste M, additional, Hendriks, Astrid, additional, Pannekoek, Yvonne, additional, de Bruin, Marjolein S, additional, van Wijk, Femke, additional, and van Sorge, Nina M., additional

Published
2024
Full Text
View/download PDF

4. Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay Registry

Author

Unit Opleiding Dermatologie, Infection & Immunity, MS Dermatologie/Allergologie, Zhang, Junfen, Boesjes, Celeste M, Loman, Laura, Kamphuis, Esmé, Romeijn, Margreet L E, Spekhorst, Lotte S, Haeck, Inge, van der Gang, Lian F, Dekkers, Coco C, van der Rijst, Lisa P, Oosting, Albert J, van Lumig, Paula, van Lynden-van Nes, Anneke M T, Tupker, Ron A, Nijssen, Annieke, Flinterman, Annebeth, Politiek, Klaziena, Touwslager, Wouter R H, Christoffers, Wianda A, Stewart, Shiarra M, Kamsteeg, Marijke, de Graaf, Marlies, de Bruin-Weller, Marjolein S, Schuttelaar, Marie-Louise A, Unit Opleiding Dermatologie, Infection & Immunity, MS Dermatologie/Allergologie, Zhang, Junfen, Boesjes, Celeste M, Loman, Laura, Kamphuis, Esmé, Romeijn, Margreet L E, Spekhorst, Lotte S, Haeck, Inge, van der Gang, Lian F, Dekkers, Coco C, van der Rijst, Lisa P, Oosting, Albert J, van Lumig, Paula, van Lynden-van Nes, Anneke M T, Tupker, Ron A, Nijssen, Annieke, Flinterman, Annebeth, Politiek, Klaziena, Touwslager, Wouter R H, Christoffers, Wianda A, Stewart, Shiarra M, Kamsteeg, Marijke, de Graaf, Marlies, de Bruin-Weller, Marjolein S, and Schuttelaar, Marie-Louise A

Published
2024

5. Differential dynamics of TARC during JAK-inhibitor therapy compared to biological therapies targeting type 2 inflammation

Author

Infection & Immunity, MS Dermatologie/Allergologie, Unit Opleiding Dermatologie, CTI Research, CTI Van Wijk, Child Health, Boesjes, Celeste M, Bakker, Daphne S, Knol, Edward F, de Graaf, Marlies, van Wijk, Femke, de Bruin-Weller, Marjolein S, Infection & Immunity, MS Dermatologie/Allergologie, Unit Opleiding Dermatologie, CTI Research, CTI Van Wijk, Child Health, Boesjes, Celeste M, Bakker, Daphne S, Knol, Edward F, de Graaf, Marlies, van Wijk, Femke, and de Bruin-Weller, Marjolein S

Published
2024

6. Effectiveness of antibacterial therapeutic clothing vs. nonantibacterial therapeutic clothing in patients with moderate-to-severe atopic dermatitis: a randomized controlled observer-blind pragmatic trial (ABC trial)

Author

MS Dermatologie/Allergologie, Infection & Immunity, Lab Dermatologie/Allergologie, Ragamin, Aviël, Schappin, Renske, de Graaf, Marlies, Tupker, Ron A., Fieten, Karin B., van Mierlo, Minke M.F., Bronner, Madelon B., Romeijn, Geertruida L.E., Sloot, Manon M., Boesjes, Celeste M., van der Rijst, Lisa P., Arents, Bernd W.M., Rustemeyer, Thomas, Schuttelaar, Marie L.A., Pasmans, Suzanne G.M.A., MS Dermatologie/Allergologie, Infection & Immunity, Lab Dermatologie/Allergologie, Ragamin, Aviël, Schappin, Renske, de Graaf, Marlies, Tupker, Ron A., Fieten, Karin B., van Mierlo, Minke M.F., Bronner, Madelon B., Romeijn, Geertruida L.E., Sloot, Manon M., Boesjes, Celeste M., van der Rijst, Lisa P., Arents, Bernd W.M., Rustemeyer, Thomas, Schuttelaar, Marie L.A., and Pasmans, Suzanne G.M.A.

Published
2024

7. Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry

Author

MS Dermatologie/Allergologie, Infection & Immunity, Kamphuis, Esmé, Boesjes, Celeste M, Loman, Laura, Kamsteeg, Marijke, Haeck, Inge, Van Lynden-van Nes, Anneke M T, Politiek, Klaziena, Van der Gang, Liana F, De Graaf, Marlies, De Bruin-Weller, Marjolein S, Schuttelaar, Marie L A, MS Dermatologie/Allergologie, Infection & Immunity, Kamphuis, Esmé, Boesjes, Celeste M, Loman, Laura, Kamsteeg, Marijke, Haeck, Inge, Van Lynden-van Nes, Anneke M T, Politiek, Klaziena, Van der Gang, Liana F, De Graaf, Marlies, De Bruin-Weller, Marjolein S, and Schuttelaar, Marie L A

Published
2024

8. The effectiveness of antibacterial therapeutic clothing compared with non-antibacterial therapeutic clothing in patients with moderate-to-severe atopic dermatitis: A randomized controlled, observer-blind pragmatic trial (ABC trial)

Author

Ragamin, Aviël; https://orcid.org/0000-0003-3120-6653, Schappin, Renske, de Graaf, Marlies, Tupker, Ron A, Fieten, Karin B; https://orcid.org/0000-0003-3790-7581, van Mierlo, Minke M F; https://orcid.org/0000-0001-5397-7382, Bronner, Madelon B, Romeijn, Geertruida L E; https://orcid.org/0000-0003-4408-8596, Sloot, Manon M, Boesjes, Celeste M, van der Rijst, Lisa, Arents, Bernd W M; https://orcid.org/0000-0001-6884-8014, Rustemeyer, Thomas; https://orcid.org/0000-0001-7580-0684, Schuttelaar, Marie L A; https://orcid.org/0000-0002-0766-4382, Pasmans, Suzanne G M A, Ragamin, Aviël; https://orcid.org/0000-0003-3120-6653, Schappin, Renske, de Graaf, Marlies, Tupker, Ron A, Fieten, Karin B; https://orcid.org/0000-0003-3790-7581, van Mierlo, Minke M F; https://orcid.org/0000-0001-5397-7382, Bronner, Madelon B, Romeijn, Geertruida L E; https://orcid.org/0000-0003-4408-8596, Sloot, Manon M, Boesjes, Celeste M, van der Rijst, Lisa, Arents, Bernd W M; https://orcid.org/0000-0001-6884-8014, Rustemeyer, Thomas; https://orcid.org/0000-0001-7580-0684, Schuttelaar, Marie L A; https://orcid.org/0000-0002-0766-4382, and Pasmans, Suzanne G M A

Abstract

BACKGROUND Increased Staphylococcus aureus (SA) colonization is considered an important factor in the pathogenesis of atopic dermatitis (AD). Antibacterial therapeutic clothing aims to reduce SA colonization and AD inflammation, however its role in the management of AD remains poorly understood. OBJECTIVE To investigate the effectiveness of antibacterial therapeutic clothing plus standard topical treatment in patients with moderate-to-severe AD, compared to standard therapeutic clothing plus standard topical treatment. If effectiveness is demonstrated, the cost-effectiveness will be evaluated. METHODS A pragmatic, double-blinded, multicenter, randomized, controlled, trial (NCT04297215) was conducted in patients of all ages with moderate-to-severe AD. Patients were centrally randomized 1:1:1 to receive standard therapeutic clothing, antibacterial clothing based on chitosan or silver. The primary outcome was the between-group difference in Eczema Area and Severity Index (EASI) measured over 52 weeks. Secondary outcomes included patient-reported outcomes, topical corticosteroid use, SA colonization, safety, and cost-effectiveness. Outcomes were assessed by means of (generalized) linear mixed model analyses. RESULTS Between March 16, 2020, and December 20, 2021, 171 patients were enrolled. In the analyses 159 patients were included (n=54 in the standard therapeutic clothing group, n=50 in the chitosan group and n=55 in the silver group). Adherence was high (median: 7 nights/week, IQR: 3-7). Median EASI scores at baseline, 4, 12, 26 and 52 weeks were in the standard therapeutic clothing group 11.8, 4.3, 4.6, 4.2, 3.6 compared to 11.3, 5.0, 3.0, 3.0, 4.4 in the chitosan and 11.6, 5.0, 5.4, 4.6 and 5.8 in the silver group. No differences in EASI over 52 weeks between the standard therapeutic clothing, chitosan (-0.1, 95%CI: -0.3 to 0.2, p=0.53), and silver group (-0.1, 95%CI: -0.3 to 0.2, p=0.58) were found. However, a small significant (P=0.035) group-by-time interaction

Published
2024

9. Effectiveness of antibacterial therapeutic clothing vs. nonantibacterial therapeutic clothing in patients with moderate-to-severe atopic dermatitis:a randomized controlled observer-blind pragmatic trial (ABC trial)

Author

Ragamin, Aviël, Schappin, Renske, de Graaf, Marlies, Tupker, Ron A., Fieten, Karin B., van Mierlo, Minke M.F., Bronner, Madelon B., Romeijn, Geertruida L.E., Sloot, Manon M., Boesjes, Celeste M., van der Rijst, Lisa P., Arents, Bernd W.M., Rustemeyer, Thomas, Schuttelaar, Marie L.A., Pasmans, Suzanne G.M.A., Ragamin, Aviël, Schappin, Renske, de Graaf, Marlies, Tupker, Ron A., Fieten, Karin B., van Mierlo, Minke M.F., Bronner, Madelon B., Romeijn, Geertruida L.E., Sloot, Manon M., Boesjes, Celeste M., van der Rijst, Lisa P., Arents, Bernd W.M., Rustemeyer, Thomas, Schuttelaar, Marie L.A., and Pasmans, Suzanne G.M.A.

Abstract

Background:Increased Staphylococcus aureus (SA) colonization is considered an important factor in the pathogenesis of atopic dermatitis (AD). Antibacterial therapeutic clothing aims to reduce SA colonization and AD inflammation; however, its role in the management of AD remains poorly understood. Objectives:To investigate the effectiveness of antibacterial therapeutic clothing+standard topical treatment in patients with moderate-to-severe AD vs. standard therapeutic clothing+standard topical treatment; and, if effectiveness was demonstrated, to demonstrate its cost-effectiveness. Methods:A pragmatic double-blinded multicentre randomized controlled trial (NCT04297215) was conducted in patients of all ages with moderate-to-severe AD. Patients were centrally randomized 1:1:1 to receive standard therapeutic clothing or antibacterial clothing based on chitosan or silver. The primary outcome was the between-group difference in Eczema Area and Severity Index (EASI) measured over 52 weeks. Secondary outcomes included patient-reported outcomes (PROs), topical corticosteroid (TCS) use, SA colonization, safety and cost-effectiveness. Outcomes were assessed by means of (generalized) linear mixed-model analyses. Results:Between 16 March 2020 and 20 December 2021, 171 patients were enrolled. In total, 159 patients were included (54 in the standard therapeutic clothing group, 50 in the chitosan group and 55 in the silver group). Adherence was high [median 7 nights a week wear (interquartile range 3–7)]. Median EASI scores at baseline and at 4, 12, 26 and 52 weeks were 11.8, 4.3, 4.6, 4.2 and 3.6, respectively, in the standard therapeutic clothing group vs. 11.3, 5.0, 3.0, 3.0 and 4.4, respectively, in the chitosan group, and 11.6, 5.0, 5.4, 4.6 and 5.8, respectively, in the silver group. No differences in EASI over 52 weeks between the standard therapeutic clothing group, the chitosan group [–0.1, 95%

Published
2024

10. Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry

Author

Kamphuis, Esmé, primary, Boesjes, Celeste M., additional, Loman, Laura, additional, Kamsteeg, Marijke, additional, Haeck, Inge, additional, Van Lynden-van Nes, Anneke M.T., additional, Politiek, Klaziena, additional, Van der Gang, Liana F., additional, De Graaf, Marlies, additional, De Bruin-Weller, Marjolein S., additional, and Schuttelaar, Marie L.A., additional

Published
2024
Full Text
View/download PDF

11. Dupilumab in daily practice for the treatment of Pediatric Atopic Dermatitis: 16-week clinical and biomarker results from the BioDay registry

Author

Kamphuis, Esmé, primary, Boesjes, Celeste M., additional, Loman, Laura, additional, Bakker, Daphne, additional, Poelhekken, Mila, additional, Zuithoff, Nicolaas, additional, Kamsteeg, Marijke, additional, Romeijn, Geertruida, additional, Wijk, Femke van, additional, Bruin-Weller, Marjolein de, additional, Graaf, Marlies de, additional, and Schuttelaar, Marie, additional

Published
2024
Full Text
View/download PDF

12. Effectiveness of antibacterial therapeutic clothing vs. nonantibacterial therapeutic clothing in patients with moderate-to-severe atopic dermatitis: a randomized controlled observer-blind pragmatic trial (ABC trial)

Author

Ragamin, Aviël, primary, Schappin, Renske, additional, de Graaf, Marlies, additional, Tupker, Ron A, additional, Fieten, Karin B, additional, van Mierlo, Minke M F, additional, Bronner, Madelon B, additional, Romeijn, Geertruida L E, additional, Sloot, Manon M, additional, Boesjes, Celeste M, additional, van der Rijst, Lisa P, additional, Arents, Bernd W M, additional, Rustemeyer, Thomas, additional, Schuttelaar, Marie L A, additional, and Pasmans, Suzanne G M A, additional

Published
2023
Full Text
View/download PDF

14. Effectiveness of antibacterial therapeutic clothing vs. nonantibacterial therapeutic clothing in patients with moderate-to-severe atopic dermatitis: a randomized controlled observer-blind pragmatic trial (ABC trial).

Author

Ragamin, Aviël, Schappin, Renske, Graaf, Marlies de, Tupker, Ron A, Fieten, Karin B, Mierlo, Minke M F van, Bronner, Madelon B, Romeijn, Geertruida L E, Sloot, Manon M, Boesjes, Celeste M, Rijst, Lisa P van der, Arents, Bernd W M, Rustemeyer, Thomas, Schuttelaar, Marie L A, and Pasmans, Suzanne G M A

Subjects
ATOPIC dermatitis, CLOTHING & dress, ANTIBACTERIAL agents, STAPHYLOCOCCUS aureus, LINEAR statistical models
Abstract

Background Increased Staphylococcus aureus (SA) colonization is considered an important factor in the pathogenesis of atopic dermatitis (AD). Antibacterial therapeutic clothing aims to reduce SA colonization and AD inflammation; however, its role in the management of AD remains poorly understood. Objectives To investigate the effectiveness of antibacterial therapeutic clothing + standard topical treatment in patients with moderate-to-severe AD vs. standard therapeutic clothing + standard topical treatment; and, if effectiveness was demonstrated, to demonstrate its cost-effectiveness. Methods A pragmatic double-blinded multicentre randomized controlled trial (NCT04297215) was conducted in patients of all ages with moderate-to-severe AD. Patients were centrally randomized 1 : 1 : 1 to receive standard therapeutic clothing or antibacterial clothing based on chitosan or silver. The primary outcome was the between-group difference in Eczema Area and Severity Index (EASI) measured over 52 weeks. Secondary outcomes included patient-reported outcomes (PROs), topical corticosteroid (TCS) use, SA colonization, safety and cost-effectiveness. Outcomes were assessed by means of (generalized) linear mixed-model analyses. Results Between 16 March 2020 and 20 December 2021, 171 patients were enrolled. In total, 159 patients were included (54 in the standard therapeutic clothing group, 50 in the chitosan group and 55 in the silver group). Adherence was high [median 7 nights a week wear (interquartile range 3–7)]. Median EASI scores at baseline and at 4, 12, 26 and 52 weeks were 11.8, 4.3, 4.6, 4.2 and 3.6, respectively, in the standard therapeutic clothing group vs. 11.3, 5.0, 3.0, 3.0 and 4.4, respectively, in the chitosan group, and 11.6, 5.0, 5.4, 4.6 and 5.8, respectively, in the silver group. No differences in EASI over 52 weeks between the standard therapeutic clothing group, the chitosan group [–0.1, 95% confidence interval (CI) –0.3 to 0.2; P = 0.53] or the silver group (–0.1, 95% CI –0.3 to 0.2; P = 0.58) were found. However, a small significant group × time interaction effect between the standard and silver groups was found (P = 0.03), in which the silver group performed worse after 26 weeks. No differences between groups were found in PROs, TCS use, SA skin colonization and healthcare utilization. No severe adverse events or silver absorption were observed. Conclusions The results of this study suggest no additional benefits of antibacterial agents in therapeutic clothing in patients with moderate-to-severe AD. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Dupilumab-Associated Lymphoid Reactions in Patients With Atopic Dermatitis

Author

Infection & Immunity, MS Dermatologie/Allergologie, Unit Opleiding Dermatologie, Geneeskunde, Pathologie Pathologen staf, Cancer, Boesjes, Celeste M, van der Gang, Lian F, Bakker, Daphne S, Ten Cate, Tess A, Spekhorst, Lotte S, de Graaf, Marlies, van Dijk, Marijke R, de Bruin-Weller, Marjolein S, Infection & Immunity, MS Dermatologie/Allergologie, Unit Opleiding Dermatologie, Geneeskunde, Pathologie Pathologen staf, Cancer, Boesjes, Celeste M, van der Gang, Lian F, Bakker, Daphne S, Ten Cate, Tess A, Spekhorst, Lotte S, de Graaf, Marlies, van Dijk, Marijke R, and de Bruin-Weller, Marjolein S

Published
2023

16. Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry

Author

MS Dermatologie/Allergologie, Infection & Immunity, Biostatistiek Onderzoek, Other research (not in main researchprogram), Unit Opleiding Dermatologie, Spekhorst, Lotte S, Boesjes, Celeste M, Loman, Laura, Zuithoff, Nicolaas P A, Bakker, Daphne S, Kamphuis, Esmé, Kamsteeg, Marijke, Haeck, Inge, Oosting, Albert J, van Lumig, Paula P M, van Lynden-van Nes, Anneke M T, Tupker, Ron A, Flinterman, Annebeth, Garritsen, Floor M, Touwslager, Wouter R H, de Bruin-Weller, Marjolein S, Schuttelaar, Marie-Louise, de Graaf, Marlies, MS Dermatologie/Allergologie, Infection & Immunity, Biostatistiek Onderzoek, Other research (not in main researchprogram), Unit Opleiding Dermatologie, Spekhorst, Lotte S, Boesjes, Celeste M, Loman, Laura, Zuithoff, Nicolaas P A, Bakker, Daphne S, Kamphuis, Esmé, Kamsteeg, Marijke, Haeck, Inge, Oosting, Albert J, van Lumig, Paula P M, van Lynden-van Nes, Anneke M T, Tupker, Ron A, Flinterman, Annebeth, Garritsen, Floor M, Touwslager, Wouter R H, de Bruin-Weller, Marjolein S, Schuttelaar, Marie-Louise, and de Graaf, Marlies

Published
2023

17. Muscle and joint pain during dupilumab treatment for atopic dermatitis: Lack of association with antinuclear antibodies

Author

Infection & Immunity, MS Dermatologie/Allergologie, Unit Opleiding Dermatologie, CTI Van Wijk, Child Health, Boesjes, Celeste M, van Emst, Madelon, Bakker, Daphne S, Spekhorst, Lotte S, van Wijk, Femke, de Graaf, Marlies, de Bruin-Weller, Marjolein S, Infection & Immunity, MS Dermatologie/Allergologie, Unit Opleiding Dermatologie, CTI Van Wijk, Child Health, Boesjes, Celeste M, van Emst, Madelon, Bakker, Daphne S, Spekhorst, Lotte S, van Wijk, Femke, de Graaf, Marlies, and de Bruin-Weller, Marjolein S

Published
2023

18. Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry

Author

MS Dermatologie/Allergologie, Infection & Immunity, Biostatistiek Onderzoek, Other research (not in main researchprogram), Unit Opleiding Dermatologie, Boesjes, Celeste M, Van der Gang, Liana F, Zuithoff, Nicolaas P A, Bakker, Daphne S, Spekhorst, Lotte S, Haeck, Inge, Kamsteeg, Marijke, De Graaf, Marlies, De Bruin-Weller, Marjolein S, MS Dermatologie/Allergologie, Infection & Immunity, Biostatistiek Onderzoek, Other research (not in main researchprogram), Unit Opleiding Dermatologie, Boesjes, Celeste M, Van der Gang, Liana F, Zuithoff, Nicolaas P A, Bakker, Daphne S, Spekhorst, Lotte S, Haeck, Inge, Kamsteeg, Marijke, De Graaf, Marlies, and De Bruin-Weller, Marjolein S

Published
2023

19. Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry

Author

Spekhorst, Lotte S, primary, Boesjes, Celeste M, additional, Loman, Laura, additional, Zuithoff, Nicolaas P A, additional, Bakker, Daphne S, additional, Kamphuis, Esmé, additional, Kamsteeg, Marijke, additional, Haeck, Inge M, additional, Oosting, Albert J, additional, van Lumig, Paula P M, additional, van Lynden-van Nes, Anneke M T, additional, Tupker, Ron A, additional, Flinterman, Annebeth, additional, Garritsen, Floor M, additional, Touwslager, Wouter R H, additional, de Bruin-Weller, Marjolein S, additional, Schuttelaar, Marie-Louise A, additional, and de Graaf, Marlies, additional

Published
2023
Full Text
View/download PDF

20. Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry

Author

Boesjes, Celeste M., primary, Van der Gang, Liana F., additional, Zuithoff, Nicolaas P.A., additional, Bakker, Daphne S., additional, Spekhorst, Lotte S., additional, Haeck, Inge, additional, Kamsteeg, Marijke, additional, De Graaf, Marlies, additional, and De Bruin-Weller, Marjolein S., additional

Published
2023
Full Text
View/download PDF

22. Association of Serum Dupilumab Levels at 16 Weeks With Treatment Response and Adverse Effects in Patients With Atopic Dermatitis

Author

Spekhorst, Lotte S., primary, de Graaf, Marlies, additional, Loeff, Floris, additional, Zuithoff, Nicolaas P. A., additional, Bakker, Daphne, additional, Boesjes, Celeste M., additional, Thijs, Judith, additional, Achten, Roselie, additional, van Wijk, Femke, additional, Rispens, Theo, additional, and de Bruin-Weller, Marjolein S., additional

Published
2022
Full Text
View/download PDF

23. Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28‐week clinical and biomarker results from the BioDay registry

Author

Kamphuis, Esmé, primary, Boesjes, Celeste M., additional, Loman, Laura, additional, Bakker, Daphne S., additional, Poelhekken, Mila, additional, Zuithoff, Nicolaas P. A., additional, Kamsteeg, Marijke, additional, Romeijn, Geertruida L. E., additional, van Wijk, Femke, additional, de Bruin‐Weller, Marjolein S., additional, de Graaf, Marlies, additional, and Schuttelaar, Marie L. A., additional

Published
2022
Full Text
View/download PDF

24. Differential dynamics of TARC during JAK‐inhibitor therapy compared to biological therapies targeting type 2 inflammation.

Author

Boesjes, Celeste M., Bakker, Daphne S., Knol, Edward F., de Graaf, Marlies, van Wijk, Femke, and de Bruin‐Weller, Marjolein S.

Subjects
*BIOTHERAPY, *INFLAMMATION, *ECZEMA
Abstract

This article discusses the use of thymus and activation-regulated chemokine (TARC) as a biomarker for atopic dermatitis (AD) patients undergoing different treatments. The study found that AD patients treated with Janus kinase (JAK) inhibitors had persistently high or increased serum TARC levels despite clinical improvement, raising questions about the reliability of TARC as a biomarker in these patients. In contrast, patients treated with biological therapies such as dupilumab or tralokinumab showed a substantial decrease in serum TARC levels. The authors suggest that further research is needed to understand the underlying mechanisms and evaluate the safety of JAK inhibitors. [Extracted from the article]

Published
2024
Full Text
View/download PDF

25. Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry

Author

Boesjes, Celeste M., primary, Kamphuis, Esmé, additional, Zuithoff, Nicolaas P.A., additional, Bakker, Daphne S., additional, Loman, Laura, additional, Spekhorst, Lotte S., additional, Haeck, Inge, additional, Kamsteeg, Marijke, additional, Van Lynden-van Nes, Anneke M.T., additional, Garritsen, Floor M., additional, Politiek, Klaziena, additional, Oldhoff, Marja, additional, De Graaf, Marlies, additional, Schuttelaar, Marie L.A., additional, and De Bruin-Weller, Marjolein S., additional

Published
2022
Full Text
View/download PDF

26. Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis

Author

Spekhorst, Lotte S., primary, de Graaf, Marlies, additional, Zuithoff, Nicolaas P. A., additional, van den Reek, Juul M. P. A., additional, Kamsteeg, Marijke, additional, Boesjes, Celeste M., additional, Romeijn, Geertruida L. E., additional, Loman, Laura, additional, Haeck, Inge, additional, Oosting, Albert J., additional, de Boer-Brand, Astrid, additional, Touwslager, Wouter R. H., additional, Flinterman, Annebeth, additional, van Lynden-van Nes, Anneke M. T., additional, Gostynski, Antoni H., additional, de Bruin-Weller, Marjolein S., additional, and Schuttelaar, Marie-Louise, additional

Published
2022
Full Text
View/download PDF

27. Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis

Author

Spekhorst, Lotte S., primary, Bakker, Daphne, additional, Drylewicz, Julia, additional, Rispens, Theo, additional, Loeff, Floris, additional, Boesjes, Celeste M., additional, Thijs, Judith, additional, Romeijn, Geertruida L. E., additional, Loman, Laura, additional, Schuttelaar, Marie‐Louise, additional, van Wijk, Femke, additional, de Graaf, Marlies, additional, and de Bruin‐Weller, Marjolein S., additional

Published
2022
Full Text
View/download PDF

28. Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay Registry

Author

Spekhorst, Lotte S, de Graaf, Marlies, Zuithoff, Nicolaas P A, van den Reek, Juul M P A, Kamsteeg, Marijke, Boesjes, Celeste M, Romeijn, Geertruida L E, Loman, Laura, Haeck, Inge, Oosting, Albert J, de Boer-Brand, Astrid, Touwslager, Wouter R H, Flinterman, Annebeth, van Lynden-van Nes, Anneke M T, Gostynski, Antoni H, de Bruin-Weller, Marjolein S, Schuttelaar, Marie-Louise, Spekhorst, Lotte S, de Graaf, Marlies, Zuithoff, Nicolaas P A, van den Reek, Juul M P A, Kamsteeg, Marijke, Boesjes, Celeste M, Romeijn, Geertruida L E, Loman, Laura, Haeck, Inge, Oosting, Albert J, de Boer-Brand, Astrid, Touwslager, Wouter R H, Flinterman, Annebeth, van Lynden-van Nes, Anneke M T, Gostynski, Antoni H, de Bruin-Weller, Marjolein S, and Schuttelaar, Marie-Louise

Abstract

Importance: Long-term data on dupilumab drug survival in patients with atopic dermatitis (AD) are scarce. Furthermore, little is known about the factors associated with drug survival of dupilumab in AD.Objective: To describe the drug survival of dupilumab in patients with AD and to identify associated predictors.Design, Setting, and Participants: This cohort study was based on data from the multicenter prospective daily practice BioDay registry, in which 4 university and 10 nonuniversity hospitals in the Netherlands participated. Analysis included patients (age ≥18 years) participating in the BioDay registry with a follow-up of at least 4 weeks. The first patient treated with dupilumab was recorded in the BioDay registry in October 2017; data lock took place in December 2020, and data analysis was performed from October 2017 to December 2020.Main Outcomes and Measures: Drug survival was analyzed by Kaplan-Meier survival curves and associated characteristics by using univariate and multivariate Cox regression analysis.Results: A total of 715 adult patients with AD (mean [SD] age, 41.8 [16.0] years; 418 [58.5%] were male) were included with a 1-year, 2-year, and 3-year overall dupilumab drug survival of 90.3%, 85.9%, and 78.6%, respectively. Characteristics associated with shorter drug survival owing to ineffectiveness were the use of immunosuppressant drugs at baseline (hazard ratio [HR], 2.64; 95% CI, 1.10-6.37) and being a nonresponder at 4 weeks (HR, 8.68; 95% CI, 2.97-25.35). Characteristics associated with shorter drug survival owing to adverse effects were the use of immunosuppressant drugs at baseline (HR, 2.69; 95% CI, 1.32-5.48), age 65 years or older (HR, 2.94; 95% CI, 1.10-7.87), and Investigator Global Assessment score of very severe AD (HR, 3.51; 95% CI, 1.20-10.28).Conclusions and Relevance: This cohort study demonstrated a good overall 1-year, 2-year, and 3-year dupilumab drug survival. Patients using immunosuppres

Published
2022

29. Eczema control and treatment satisfaction in atopic dermatitis patients treated with dupilumab - a cross-sectional study from the BioDay registry

Author

Infection & Immunity, MS Dermatologie/Allergologie, Oosterhaven, Jart A F, Spekhorst, Lotte S, Zhang, Junfen, Voorberg, Angelique N, Romeijn, Geertruida L E, Boesjes, Celeste M, de Graaf, Marlies, de Bruin-Weller, Marjolein S, Schuttelaar, Marie L A, Infection & Immunity, MS Dermatologie/Allergologie, Oosterhaven, Jart A F, Spekhorst, Lotte S, Zhang, Junfen, Voorberg, Angelique N, Romeijn, Geertruida L E, Boesjes, Celeste M, de Graaf, Marlies, de Bruin-Weller, Marjolein S, and Schuttelaar, Marie L A

Published
2022

30. Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry

Author

MS Dermatologie/Allergologie, Infection & Immunity, Unit Opleiding Dermatologie, Biostatistiek Onderzoek, Other research (not in main researchprogram), CTI Van Wijk, Child Health, Kamphuis, Esmé, Boesjes, Celeste M., Loman, Laura, Bakker, Daphne S., Poelhekken, Mila, Zuithoff, Nicolaas P.A., Kamsteeg, Marijke, Romeijn, Geertruida L.E., van Wijk, Femke, de Bruin-Weller, Marjolein S., de Graaf, Marlies, Schuttelaar, Marie L.A., MS Dermatologie/Allergologie, Infection & Immunity, Unit Opleiding Dermatologie, Biostatistiek Onderzoek, Other research (not in main researchprogram), CTI Van Wijk, Child Health, Kamphuis, Esmé, Boesjes, Celeste M., Loman, Laura, Bakker, Daphne S., Poelhekken, Mila, Zuithoff, Nicolaas P.A., Kamsteeg, Marijke, Romeijn, Geertruida L.E., van Wijk, Femke, de Bruin-Weller, Marjolein S., de Graaf, Marlies, and Schuttelaar, Marie L.A.

Published
2022

31. Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry

Author

MS Dermatologie/Allergologie, Infection & Immunity, Biostatistiek Onderzoek, Other research (not in main researchprogram), Unit Opleiding Dermatologie, Boesjes, Celeste M., Kamphuis, Esmé, Zuithoff, Nicolaas P.A., Bakker, Daphne S., Loman, Laura, Spekhorst, Lotte S., Haeck, Inge, Kamsteeg, Marijke, VAN LYNDEN-VAN NES, Anneke M.T., Garritsen, Floor M., Politiek, Klaziena, Oldhoff, Marja, DE GRAAF, Marlies, Schuttelaar, Marie L.A., DE BRUIN-WELLER, Marjolein S., MS Dermatologie/Allergologie, Infection & Immunity, Biostatistiek Onderzoek, Other research (not in main researchprogram), Unit Opleiding Dermatologie, Boesjes, Celeste M., Kamphuis, Esmé, Zuithoff, Nicolaas P.A., Bakker, Daphne S., Loman, Laura, Spekhorst, Lotte S., Haeck, Inge, Kamsteeg, Marijke, VAN LYNDEN-VAN NES, Anneke M.T., Garritsen, Floor M., Politiek, Klaziena, Oldhoff, Marja, DE GRAAF, Marlies, Schuttelaar, Marie L.A., and DE BRUIN-WELLER, Marjolein S.

Published
2022

32. Association of Serum Dupilumab Levels at 16 Weeks with Treatment Response and Adverse Effects in Patients with Atopic Dermatitis: A Prospective Clinical Cohort Study from the BioDay Registry

Author

MS Dermatologie/Allergologie, Infection & Immunity, Biostatistiek Onderzoek, Other research (not in main researchprogram), Unit Opleiding Dermatologie, CTI Van Wijk, Child Health, Spekhorst, Lotte S., De Graaf, Marlies, Loeff, Floris, Zuithoff, Nicolaas P.A., Bakker, Daphne, Boesjes, Celeste M., Thijs, Judith, Achten, Roselie, Van Wijk, Femke, Rispens, Theo, De Bruin-Weller, Marjolein S., MS Dermatologie/Allergologie, Infection & Immunity, Biostatistiek Onderzoek, Other research (not in main researchprogram), Unit Opleiding Dermatologie, CTI Van Wijk, Child Health, Spekhorst, Lotte S., De Graaf, Marlies, Loeff, Floris, Zuithoff, Nicolaas P.A., Bakker, Daphne, Boesjes, Celeste M., Thijs, Judith, Achten, Roselie, Van Wijk, Femke, Rispens, Theo, and De Bruin-Weller, Marjolein S.

Published
2022

33. Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay Registry

Author

MS Dermatologie/Allergologie, Infection & Immunity, Biostatistiek Onderzoek, Other research (not in main researchprogram), Spekhorst, Lotte S, de Graaf, Marlies, Zuithoff, Nicolaas P A, van den Reek, Juul M P A, Kamsteeg, Marijke, Boesjes, Celeste M, Romeijn, Geertruida L E, Loman, Laura, Haeck, Inge, Oosting, Albert J, de Boer-Brand, Astrid, Touwslager, Wouter R H, Flinterman, Annebeth, van Lynden-van Nes, Anneke M T, Gostynski, Antoni H, de Bruin-Weller, Marjolein S, Schuttelaar, Marie-Louise, MS Dermatologie/Allergologie, Infection & Immunity, Biostatistiek Onderzoek, Other research (not in main researchprogram), Spekhorst, Lotte S, de Graaf, Marlies, Zuithoff, Nicolaas P A, van den Reek, Juul M P A, Kamsteeg, Marijke, Boesjes, Celeste M, Romeijn, Geertruida L E, Loman, Laura, Haeck, Inge, Oosting, Albert J, de Boer-Brand, Astrid, Touwslager, Wouter R H, Flinterman, Annebeth, van Lynden-van Nes, Anneke M T, Gostynski, Antoni H, de Bruin-Weller, Marjolein S, and Schuttelaar, Marie-Louise

Published
2022

34. Ocular surface disease is common in moderate-to-severe atopic dermatitis patients

Author

MS Dermatologie/Allergologie, Infection & Immunity, Unit Opleiding Dermatologie, MS Oogheelkunde, Other research (not in main researchprogram), CTI Van Wijk, Child Health, Biostatistiek Onderzoek, Julius Centrum, Achten, Roselie E, Bakker, Daphne S, van Luijk, Chantal M, van der Wal, M Marlot, de Graaf, Marlies, van Wijk, Femke, Zuithoff, Nicolaas P A, van der Rijst, Lisa P, Boesjes, Celeste M, Thijs, Judith L, de Boer, Joke H, de Bruin-Weller, Marjolein S, MS Dermatologie/Allergologie, Infection & Immunity, Unit Opleiding Dermatologie, MS Oogheelkunde, Other research (not in main researchprogram), CTI Van Wijk, Child Health, Biostatistiek Onderzoek, Julius Centrum, Achten, Roselie E, Bakker, Daphne S, van Luijk, Chantal M, van der Wal, M Marlot, de Graaf, Marlies, van Wijk, Femke, Zuithoff, Nicolaas P A, van der Rijst, Lisa P, Boesjes, Celeste M, Thijs, Judith L, de Boer, Joke H, and de Bruin-Weller, Marjolein S

Published
2022

35. Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis

Author

MS Dermatologie/Allergologie, Infection & Immunity, Unit Opleiding Dermatologie, CTI Computational Immunology Core, CTI Van Wijk, Child Health, Spekhorst, Lotte S, Bakker, Daphne, Drylewicz, Julia, Rispens, Theo, Loeff, Floris, Boesjes, Celeste M, Thijs, Judith, Romeijn, Geertruida L E, Loman, Laura, Schuttelaar, Marie-Louise, van Wijk, Femke, de Graaf, Marlies, de Bruin-Weller, Marjolein S, MS Dermatologie/Allergologie, Infection & Immunity, Unit Opleiding Dermatologie, CTI Computational Immunology Core, CTI Van Wijk, Child Health, Spekhorst, Lotte S, Bakker, Daphne, Drylewicz, Julia, Rispens, Theo, Loeff, Floris, Boesjes, Celeste M, Thijs, Judith, Romeijn, Geertruida L E, Loman, Laura, Schuttelaar, Marie-Louise, van Wijk, Femke, de Graaf, Marlies, and de Bruin-Weller, Marjolein S

Published
2022

36. Ocular surface disease is common in moderate‐to‐severe atopic dermatitis patients

Author

Achten, Roselie E., primary, Bakker, Daphne S., additional, van Luijk, Chantal M., additional, van der Wal, Marlot, additional, de Graaf, Marlies, additional, van Wijk, Femke, additional, Zuithoff, Nicolaas P.A., additional, van der Rijst, Lisa P., additional, Boesjes, Celeste M., additional, Thijs, Judith L., additional, de Boer, Joke H., additional, and de Bruin‐Weller, Marjolein S., additional

Published
2022
Full Text
View/download PDF

37. Eczema control and treatment satisfaction in atopic dermatitis patients treated with dupilumab – a cross-sectional study from the BioDay registry

Author

Oosterhaven, Jart A. F., primary, Spekhorst, Lotte S., additional, Zhang, Junfen, additional, Voorberg, Angelique N., additional, Romeijn, Geertruida L. E., additional, Boesjes, Celeste M., additional, de Graaf, Marlies, additional, de Bruin-Weller, Marjolein S., additional, and Schuttelaar, Marie L. A., additional

Published
2021
Full Text
View/download PDF

38. Eczema control and treatment satisfaction in atopic dermatitis patients treated with dupilumab – a cross-sectional study from the BioDay registry.

Author

Oosterhaven, Jart A. F., Spekhorst, Lotte S., Zhang, Junfen, Voorberg, Angelique N., Romeijn, Geertruida L. E., Boesjes, Celeste M., de Graaf, Marlies, de Bruin-Weller, Marjolein S., and Schuttelaar, Marie L. A.

Subjects
PATIENT satisfaction, ATOPIC dermatitis, DUPILUMAB, PATIENT reported outcome measures, ECZEMA
Abstract

Eczema control is a new construct to be measured in atopic dermatitis (AD). Measuring patient-perceived eczema control and treatment satisfaction in AD patients, treated with dupilumab between 16 and 52 weeks. Cross-sectional questionnaire study. Patients from the Dutch BioDay registry completed the Atopic Dermatitis Control Test (ADCT), Recap of Atopic Eczema (RECAP) and Treatment Satisfaction Questionnaire for Medication, Version II (TSQM v. II), along with other Patient Reported Outcome Measures (PROMs). 104/157 patients responded (response rate 66.2%). Median ADCT score was 4 (interquartile range [IQR] 5); median RECAP score was 5 (IQR 6); median TSQM v.II global satisfaction score was 83.3 (IQR 25.0). According to the ADCT, 38.5–66.3% perceived their AD was 'in control', depending on the interpretability method used. Minimally clinically important difference (MCID) of ≥4 points for the DLQI and POEM was achieved respectively in N = 66 (84.6%) and N = 63 (78.8%) patients. When considering the favorable scores on other PROMs and the TSQM v. II, and comparing these to the relatively low percentage of patients perceiving control according to the ADCT, interpretability of eczema control still appears difficult. Treatment satisfaction in the studied cohort was high. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

40. Single-cell sequencing of human Langerhans cells identifies altered gene expression profiles in patients with atopic dermatitis.

Author

Tamminga SM, Van Der Wal MM, Saager ES, Van Der Gang LF, Boesjes CM, Hendriks A, Pannekoek Y, De Bruin MS, Van Wijk F, and Van Sorge NM

Subjects
Humans, Skin microbiology, Skin pathology, Skin immunology, Transcriptome, Male, Adult, Female, Chemokine CCL17 genetics, Chemokine CCL17 metabolism, Th2 Cells immunology, Th2 Cells metabolism, T-Lymphocytes, Regulatory immunology, T-Lymphocytes, Regulatory metabolism, Sequence Analysis, RNA, Lymphocyte Activation immunology, Dermatitis, Atopic immunology, Dermatitis, Atopic microbiology, Dermatitis, Atopic genetics, Langerhans Cells immunology, Langerhans Cells metabolism, Staphylococcus aureus immunology, Staphylococcus aureus genetics, Single-Cell Analysis
Abstract

Atopic dermatitis (AD) is characterized by dysregulated T cell immunity and skin microbiome dysbiosis with predominance of Staphylococcus aureus, which is associated with exacerbating AD skin inflammation. Specific glycosylation patterns of S. aureus cell wall structures amplify skin inflammation through interaction with Langerhans cells (LCs). Nevertheless, the role of LCs in AD remains poorly characterized. Here, we performed single cell RNA sequencing of primary epidermal LCs and dermal T cells, isolated from skin biopsies of AD patients and healthy control subjects, alongside specific glycoanalysis of S. aureus strains isolated from the AD lesions. Our findings revealed 4 LC subpopulations ie, 2 steady-state clusters [LC1 and LC1H] and 2 proinflammatory/matured subsets [LC2 and migratory LCs]. The latter 2 subsets were enriched in AD skin. AD LCs showed enhanced expression of C-type lectin receptors, the high-affinity IgE receptor, and activation of prostaglandin and leukotriene biosynthesis pathways, upregulated transcriptional signatures related to T cell activation pathways, and increased expression of CCL17 compared with healthy LCs. Correspondingly, T helper 2 and T regulatory cell populations were increased in AD lesions. Complementary, we performed bulk RNA sequencing of primary LCs stimulated with the S. aureus strains isolated from the AD lesions, which showed upregulation of T helper 2-related pathways. Our study provides proof-of-concept for a role of LCs in connecting the S. aureus-T cell axis in the AD inflammatory cycle., (© The Author(s) 2025. Published by Oxford University Press on behalf of The American Association of Immunologists.)

Published
2025
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results